SecBot SecBot

NMRA drug pipeline

$0.3700
−13.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 mixed · 2 neutral
Phase 3 trials
3
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 1b/2a
Time to marketAt least 3-5 years away, assuming successful Phase 2 and Phase 3 trials. The drug is still in early clinical development (Phase 1b/2a).

NMRA-511 Updated Sep 13

What to watch

Watch for NMRA-511 MAD expansion cohort data in Q4 2026, positive results could drive a significant rally given the stock's ~$1.04 price and 380% implied analyst upside, but negative data would pressure shares. The company has multiple shots on goal (navacaprant, NMRA-898, NMRA-215), so NMRA-511 is not a single-point-of-failure.

Bull case
  • Phase 1b data showed encouraging efficacy signals: Cohen's d effect size of 0.34 on CMAI total score and 0.51 on aggression sub-factor in Alzheimer's agitation patients, suggesting meaningful clinical benefit.
  • Massive institutional accumulation in Q2 2026: BlackRock doubled its position (+279%), Geode doubled (+140%), Citadel doubled (+141%), and many other funds added or doubled positions, signaling institutional confidence.
  • Analyst consensus is strongly bullish: 12 Buy/Strong Buy ratings vs. 2 Hold and 1 Sell, with a mean price target of $6.14 implying ~380% upside from the current ~$1.04 price.
Bear case
  • Phase 1b data is early and Cohen's d effect sizes from small studies often fail to replicate in larger, placebo-controlled Phase 2/3 trials, the 0.34-0.51 range may shrink or disappear.
  • Insider selling: COO Daljit Singh Aurora sold ~$500K+ worth of shares in mid-August 2026 at ~$1.50-1.65, well above the current ~$1.04 price, signaling insider caution.
  • The company is pre-revenue with a $43.1M quarterly net loss and $116.8M cash, at the current ~$33M quarterly burn rate, a capital raise may be needed by late 2027, causing dilution.
● neutral
Impact
PhasePreclinical / Phase 1
Time to marketUnknown — NMRA-898 is still in preclinical/Phase 1 development. If Phase 1 data is positive, Phase 2 trials would follow, meaning potential approval is likely 5+ years away, assuming successful development.

NMRA-898 Updated Sep 13

What to watch

Watch for NMRA-898 Phase 1 data readout in H2 2026 (likely Q4 2026), which will be the first clinical proof-of-concept for this M4 agonist in schizophrenia. Positive data could validate the program and drive a re-rating, but Phase 1 safety/tolerability readouts are early-stage and high-risk. The stock also has a larger binary catalyst in the NMRA-335140 (navacaprant) Phase 3 MDD data readout, which is the more consequential near-term event.

Bull case
  • NMRA-898 targets the M4 muscarinic receptor, the same mechanism validated by KarXT (xanomeline-trospium, now approved as Cobenfy for schizophrenia), which generated multi-billion-dollar commercial expectations, a successful M4 agonist could tap a large addressable market.
  • Analyst consensus is strongly bullish: 12 Buy/Strong Buy ratings vs 2 Hold and 1 Sell, with a mean price target of $6.14 (implying ~490% upside from $1.04) and a high target of $14.
  • Institutional accumulation has been notable: BlackRock doubled its position (+279%), Geode Capital doubled (+140%), and Citadel doubled (+141%) in Q2 2026, signaling institutional interest in the pipeline.
Bear case
  • NMRA-898 is still preclinical/Phase 1 with no clinical data yet, early-stage CNS drugs have a high attrition rate, and Phase 1 safety/tolerability readouts are often inconclusive.
  • Neumora's stock trades near $1.04 with a ~$320M market cap and has seen heavy insider selling: COO Daljit Singh Aurora sold ~412K shares (~$635K) over four days in August 2026, signaling limited insider confidence.
  • The company has a high short volume ratio (~44.9% weighted over 60 sessions as of Sept 11, 2026), indicating significant bearish positioning.

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Other drugs in filings and trials

no drug report yet

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
NMRA-335140Study to Assess the Safety and Effectiveness of NMRA-335140-501Phase 3Terminated904Aug 17, 2026
NMRA-335140Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderPhase 3Completed430May 6, 2026
NMRA-335140Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderPhase 3Completed422May 4, 2026
NMRA-335140 80 mgTo Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.Phase 2Completed18Apr 9, 2025